Document:

<PAGE>   1

                                                                    EXHIBIT 10.4

                       AGREEMENT CONCERNING TERMINATION OF
                          EMPLOYMENT OF GUNTER HOFMANN

The following sets forth the terms and conditions of the agreement (the
"Agreement") regarding the end of Gunter Hofmann's ("Dr. Hofmann") employment in
the position of Chief Scientific Officer of Genetronics Biomedical Ltd. and
Genetronics, Inc. (collectively, the "Company") effective as of September 7,
1999. Pursuant to Section 18 herein, the Agreement shall become effective on the
eighth day after this Agreement is executed by Dr. Hofmann (the "Effective
Date"). Gunter Hofmann and the Company hereby agree as follows:

1.      TERMINATION OF EMPLOYMENT AGREEMENT. Except for Section 5 of the
        employment agreement between Dr. Hofmann and the Company dated January
        9, 1995, as amended from time to time (the "Employment Agreement"), a
        copy of which is attached hereto as Exhibit A, the Employment Agreement
        is hereby superseded by this Agreement and is null and void and of no
        further force or effect. For the sake of clarity, Dr. Hofmann expressly
        acknowledges that Section 5 of the Employment Agreement contains
        confidentiality and non-disclosure provisions therein to which he
        remains, and shall remain, bound as set forth therein.

2.      EMPLOYMENT. Dr. Hofmann's employment as Chief Scientific Officer and all
        other employment positions Dr. Hofmann may have held with the Company
        were terminated effective as of September 7, 1999 (the "Separation
        Date").

3.      SEVERANCE PAY. The Company agrees to make severance payments to Dr.
        Hofmann in the form of: (a) continuation of his base salary in effect on
        the Separation Date for a period of sixteen (16) months from the
        Separation Date (the "Severance Period") and (b) a grant of an option to
        purchase 97,000 shares of the common stock of the Company ("New Option")
        at a price per share equal to ten percent (10%) more than the fair
        market value of the Company's common stock on the date that is the last
        trading day before the date of grant. The term of the New Options shall
        be five years from the date of grant. The New Options will vest on
        January 6, 2001, which is the last day of the Severance Period, and will
        be exerciseable for the duration of the term of the New Options.
        However, in the event the Company is acquired by, or merged with,
        another entity prior to the vesting of the New Options, the New Options
        will vest upon the completion of the merger or acquisition. The New
        Options shall be governed pursuant to the terms and conditions of the
        Genetronics Biomedical, Ltd. 1997 Stock Option Plan, as amended."The
        sixteen months of severance payments will be paid on the Company's
        ordinary payroll dates and will be subject to standard payroll
        deductions and withholdings.

4.      STOCK OPTIONS. The stock options listed in Exhibit B to this Agreement
        ("Existing Options") shall be fully vested as of the Effective Date of
        this Agreement, and changed from ISO to non-qualifying options. Other
        than as provided in this Section 4, you

                                       1
<PAGE>   2

        acknowledge that your Existing Options will continue to be governed by
        the terms and conditions of the Genetronics Biomedical, Ltd. Stock
        Option Plan under which each Existing Option was granted.

5.      ACCRUED SALARY AND VACATION. Dr. Hofmann agrees and acknowledges that
        the Company has paid him all accrued salary, and all accrued and unused
        vacation benefits earned through the Separation Date, if any, subject to
        standard payroll deductions, withholding taxes and other obligations.

6.      INSURANCE BENEFITS. To the extent provided by the federal COBRA law or,
        if applicable, state insurance laws, and by the Company's current group
        health insurance policies, Dr. Hofmann will be eligible to continue his
        health insurance benefits. Later, Dr. Hofmann may be able to convert to
        an individual policy through the provider of the Company's health
        insurance, if he wishes. Dr. Hofmann will be provided with a separate
        notice of his COBRA rights. In the event that Dr. Hofmann elects
        continued coverage under COBRA, the Company will pay his COBRA health
        insurance premiums (Company and employee contributions) for sixteen (16)
        months from the Separation Date. Thereafter, Dr. Hofmann shall be solely
        responsible for the payment of the premium for such benefits to the
        Company's health insurance provider, if Dr. Hofmann desires to continue
        such benefits.

7.      LIFE INSURANCE. The Company agrees that it will maintain a life
        insurance policy on Dr. Hofmann's life for his and his estate's benefit,
        the terms of which shall be substantially similar to terms of the
        personal policy maintained by the Company for his benefit prior to the
        Separation Date, for a period of sixteen (16) months after the
        Separation Date.

8.      COMPANY EQUIPMENT. The Company agrees that, as part of this Agreement
        and in consideration thereof, Dr. Hofmann may keep for his own personal
        use any Company computer, cellular telephone and facsimile machine
        currently in his possession.

9.      AUTOMOBILE. The Company agrees that, as part of this Agreement and in
        consideration thereof, it will continue to pay for the lease payments
        (approximate value of Fifteen Thousand Dollars ($15,000)) on the
        automobile that was obtained for Dr. Hofmann as an officer of the
        Company for the duration of the existing lease period.

10.     401(k). The Company agrees that, as part of this Agreement and in
        consideration thereof, the Company will purchase for Dr. Hofmann the
        same number of shares of common stock of the Company that he would have
        received through the Company's 401(k) plan had he remained an employee
        through January 7, 2001. Such stock shall be purchased for him quarterly
        as it is for employees who participate in the Company's 401(K) plan.

11.     OTHER COMPENSATION AND BENEFITS. Except as expressly provided herein,
        Dr. Hofmann acknowledges and agrees that he is not entitled to and will
        not receive any additional

                                       2
<PAGE>   3

        employment-related compensation, severance, stock options, stock or
        benefits from the Company after the Separation Date.

12.     NON-DISCLOSURE OF THE TERMS OF THIS AGREEMENT. The provisions of this
        Agreement shall be held in strictest confidence by Dr. Hofmann and the
        Company and shall not be publicized or disclosed in any manner
        whatsoever; provided, however, that: (a) Dr. Hofmann may disclose this
        Agreement, in confidence, to his immediate family; (b) the parties may
        disclose this Agreement in confidence to their respective attorneys,
        accountants, auditors, tax preparers, and financial advisors; (c) the
        Company may disclose this Agreement as necessary to fulfill standard or
        legally required corporate reporting or disclosure requirements; and (d)
        the parties may disclose this Agreement insofar as such disclosure may
        be necessary to enforce its terms or as otherwise required by law.

13.     NON-DISPARAGEMENT. The parties agree that neither they, nor their
        officers, directors or employees will make any disparaging statements
        about each other. However, in the interest of implementing open
        discussion and disclosure among Board members, the parties agree that
        this provision does not apply to statements made by the above
        individuals in their capacity as directors to other directors of the
        Company.

14.     NON-SOLICITATION. Dr. Hofmann agrees that for a period of one (1) year
        from the Separation Date he will not hire or take away or cause to be
        hired or taken away any employee of the Company for the purpose of
        employment in any business or endeavor. He further agrees, without
        prejudice to any and all other rights of the Company, that in the event
        of his violation or attempted violation of the covenants contained in
        this agreement, an injunction or other like remedy shall be the only
        effective method to protect the Company's and its affiliates' rights and
        property, and that an interim injunction may be granted immediately on
        the commencement of any suit.

15.     RETURN OF PROPERTY. Except as otherwise provided herein, upon the
        Effective Date, Dr. Hofmann agrees to return to the Company all Company
        documents (and all copies thereof) and other Company property in his
        possession or his control as an employee, including, but not limited to,
        Company files, business plans, notes, samples, sales notebooks,
        drawings, specifications, calculations, sequences, data,
        computer-recorded information, tangible property, including, but not
        limited to, software, credit cards, business cards, entry cards, keys
        and any other materials of any nature pertaining to his work with the
        Company as an employee, and any documents or data of any description (or
        any reproduction of any documents or data) containing or pertaining to
        any proprietary or confidential material of the Company, which is in his
        possession by nature of his employment relationship with the Company. In
        the event no property is returned, Dr. Hofmann will be deemed to have
        agreed and acknowledged that he has no Company documents of substantive
        value in his possession, other than those documents in his possession
        for reasonable use as a director or consultant.

16.     TAX CONSEQUENCES. The Company makes no representations or warranties
        with respect to the tax consequences of any payments to Dr. Hofmann
        under the terms of this

                                       3
<PAGE>   4

        Agreement. Dr. Hofmann agrees and understands that he is responsible for
        payment, if any, of local, state and/or federal taxes on the sums paid
        hereunder by the Company and any penalties or assessments thereon. Dr.
        Hofmann further agrees to indemnify and hold the Company harmless from
        any claims, demands, deficiencies, penalties, assessments, executions,
        judgments, or recoveries by any government agency against the Company
        for any amounts claimed due on account of his failure to pay federal or
        state taxes or damages sustained by the Company by reason of any such
        claims, including reasonable attorneys' fees.

17.     RELEASE OF CLAIMS AGAINST THE COMPANY. In consideration of the
        foregoing, Dr. Hofmann hereby releases, acquits, and forever discharges
        the Company, its parents and subsidiaries, and their officers,
        directors, agents, servants, employees, attorneys, shareholders,
        partners, successors, assigns, affiliates, customers, and clients of and
        from any and all claims, liabilities, demands, causes of action, costs,
        expenses, attorneys' fees, damages, indemnities and obligations of every
        kind and nature, in law, equity, or otherwise, known and unknown,
        suspected and unsuspected, disclosed and undisclosed, arising out of or
        in any way related to agreements, acts or conduct at any time prior to
        the Separation Date, including, but not limited to: all such claims and
        demands directly or indirectly arising out of or in any way connected
        with the Company's employment of Dr. Hofmann, the termination of that
        employment, the Company's performance of its obligations as his former
        employer, and any claims arising from the Employment Agreement or his
        offer letter; claims or demands related to salary, bonuses, commissions,
        stock, or any other ownership interests in the Company, vacation pay,
        fringe benefits, expense reimbursements, severance pay, or any form of
        compensation; claims pursuant to any federal, state or local law or
        cause of action including, but not limited to, the California Fair
        Employment and Housing Act, the federal Civil Rights Act of 1964, as
        amended; the federal Age Discrimination in Employment Act of 1967, as
        amended; the federal Americans With Disabilities Act; tort law; contract
        law; wrongful discharge; discrimination; harassment; fraud; defamation;
        emotional distress; and breach of the implied covenant of good faith and
        fair dealing. Notwithstanding the above, Dr. Hofmann is not hereby
        releasing any claims Dr. Hofmann may have (i) under this Agreement; (ii)
        for indemnification pursuant to and in accordance with the applicable
        statutes, the applicable terms of the charters, articles of
        incorporation or bylaws of the Company, any insurance policies
        maintained by the Company which afford coverage to Dr. Hofmann; (iii)
        for rights or claims Dr. Hofmann may have pursuant to any applicable
        stock option plans or stock option agreements Dr. Hofmann may have with
        the Company; and (iv) any criminal, grossly negligent or fraudulent
        conduct on the part of the Company, other than his own conduct, which
        creates liability on the part of Dr. Hofmann. For the sake of clarity,
        Dr. Hofmann expressly agrees that the provisions of this Section 17,
        including part (iv) herein, shall not be interpreted to permit Dr.
        Hofmann to make a claim against the Company that is related to
        termination of his employment with the Company or the Company's
        performance of its obligations as his former employer, any claims
        arising from the Employment Agreement, or any form of compensation he
        received as an employee.

                                       4
<PAGE>   5

18.     ADEA WAIVER. Dr. Hofmann further acknowledges that he is knowingly and
        voluntarily waiving and releasing any rights he may have under the Age
        Discrimination in Employment Act of 1967 ("ADEA"). He also acknowledges
        that the consideration given for the waiver and release in the preceding
        paragraphs hereof is in addition to anything of value to which he was
        already entitled. Since Dr. Hofmann is more than forty (40) years of age
        when this release is signed, he hereby provides the further
        acknowledgment that he is advised by this writing, as required by the
        Older Workers Benefit Protection Act, that: (a) his waiver and release
        do not apply to any rights or claims that may arise after the Effective
        Date of this release; (b) he has the right to consult with an attorney
        prior to executing this release (although he may voluntarily choose not
        to do so); (c) he may have at least twenty-one (21) days to consider
        this Agreement (although he may by his own choice execute this release
        earlier); (d) he has seven (7) days following the execution of this
        release to revoke this release; and (e) this Agreement shall not be
        effective until the date upon which the revocation period has expired,
        therefore making the effective date the eighth day after this release is
        signed by Dr. Hofmann (the "Effective Date").

19.     RELEASE OF CLAIMS AGAINST DR. HOFMANN. In consideration of the
        foregoing, the Company, for and on behalf of itself, its directors,
        officers, shareholders, successors and assigns hereby releases, acquits
        and forever discharges Dr. Hofmann and his assigns, transferees,
        successors, heirs, agents and attorneys from any and all claims,
        liabilities, demands, causes of action, costs, expenses, attorneys'
        fees, damages, indemnities and obligations of every kind and nature, in
        law, equity, or otherwise, known and unknown, suspected and unsuspected,
        disclosed and undisclosed, arising out of or in any way related to
        agreements, acts or conduct of Dr. Hofmann within the course and scope
        of his obligations and duties as an employee or officer of the Company
        at any time prior to the Separation Date, including, but not limited to:
        all such claims and demands directly or indirectly arising out of or in
        any way connected with the Company's employment of Dr. Hofmann, the
        termination of that employment, his performance of his obligations and
        duties as an employee, officer, and director of the Company, or arising
        out of any agreement between Dr. Hofmann and the Company, with the
        exception of any claim arising out of (i) his obligations under this
        Agreement; (ii) his obligations arising out of Section 5 of the
        Employment Agreement or any other obligations relating to the
        proprietary information of the Company; and (iii) any criminal, grossly
        negligent, or fraudulent conduct by him which creates liability on the
        part of the Company.

                                       5
<PAGE>   6

20.     SECTION 1542 WAIVER. In providing the releases set forth in Paragraphs
        16 and 18 above, the parties agree that the releases include claims
        which may be unknown to the parties at present. The parties hereby
        acknowledge that they have read and understand Section 1542 of the Civil
        Code of the State of California which reads as follows:

                      A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE
               CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE
               TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE
               MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.

21.     LEGAL ADVICE. The parties acknowledge that they have been given the
        opportunity to seek the advice of independent legal counsel with respect
        to this Agreement and they have been provided with sufficient time to
        obtain such legal advice.

22.     CONSULTING AGREEMENT. Dr. Hofmann agrees to provide consulting services
        to the Company as set forth in a separate consulting agreement.

23.     NO OTHER AGREEMENTS. The parties acknowledge and represent to each other
        that this Agreement is signed without reliance upon any promises,
        representations or warranties whatsoever, whether expressed or implied,
        which are not contained herein in writing concerning the matters herein
        set forth.

24.     ENTIRE AGREEMENT. This Agreement constitutes the complete, final and
        exclusive embodiment of the entire Agreement between the parties with
        regard to the subject matter hereof. It is entered into without reliance
        on any promise or representation, written or oral, other than those
        expressly contained herein. It may not be modified except in a writing
        signed by Dr. Hofmann and a duly authorized officer of the Company. Each
        party has carefully read this Agreement, has been afforded the
        opportunity to be advised of its meaning and consequences by his or its
        respective attorneys, and signed the same of his or its free will.

25.     APPLICABLE LAW. This Agreement shall be deemed to have been entered into
        and shall be construed and enforced in accordance with the laws of the
        State of California as applied to contracts made and to be performed
        entirely within California.

26.     SECTION HEADINGS. The section and paragraph headings contained in this
        Agreement are for reference purposes only and shall not affect in any
        way the meaning or interpretation of this Agreement.

27.     COUNTERPARTS. This Agreement may be executed in two counterparts, each
        of which shall be deemed an original, all of which together shall
        constitute one and the same instrument.

                                       6
<PAGE>   7

28.     ACKNOWLEDGMENT. By executing this Agreement, each signatory acknowledges
        that he or it has read and understands this Agreement and release and
        further acknowledges that he or it has had the opportunity to review it
        with an attorney. Each signatory further acknowledges that he or it is
        executing this Agreement and release voluntarily and with full knowledge
        of its terms and provisions and of legal rights and regard thereto.

        IN WITNESS WHEREOF, the parties have duly authorized and caused this
Agreement to be executed as follows:

Dated this 6th day of December, 1999.      Dated this 6th day of December, 1999.

                                           GENETRONICS BIOMEDICAL, LTD.

   /s/ Gunter Hofmann                      BY:     /s/  Martin Nash
-------------------------------------          ---------------------------------
GUNTER A. HOFMANN                          ITS: PRESIDENT AND CEO

Dated this 6th day of December, 1999.

GENETRONICS, INC.

BY:  /S/ MARTIN NASH
     --------------------------------
ITS: PRESIDENT AND CEO

Attachments:
Exhibit A: Employment Agreement
Exhibit B: Schedule of Outstanding Stock Options

                                       7
<PAGE>   8

                                    EXHIBIT A

                              EMPLOYMENT AGREEMENT

Filed as an exhibit to Registrant's Form 20-F for the period ended February 28,
1998

                                    EXHIBIT B

                      SCHEDULE OF OUTSTANDING STOCK OPTIONS

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------
DATE OF           PLAN            NUMBER          PRICE PER       VESTING         EXPIRATION
GRANT                             OF              SHARE
                                  OPTIONS         (US$)
<S>               <C>             <C>             <C>             <C>             <C>
--------------------------------------------------------------------------------------------
09-04-96          1995             35,000         2.27            100%            09-03-01
--------------------------------------------------------------------------------------------
01-14-97          1995             25,000         2.81            100%            01-13-02
--------------------------------------------------------------------------------------------
01-27-97          1995             45,000         3.06            100%            01-26-02
--------------------------------------------------------------------------------------------
07-08-98          1997             35,200         2.48            100%            07-07-03
--------------------------------------------------------------------------------------------
10-20-98          1997            100,000         2.95            25% *           10-19-03
--------------------------------------------------------------------------------------------
</TABLE>

* 100% TO BE VESTED AS OF THE EFFECTIVE DATE OF THIS AGREEMENT.

                                       8<PAGE>   1

                                                                    EXHIBIT 10.5

                          CONSULTING SERVICES AGREEMENT

        This Agreement is entered into effective November 5, 1999 ("Effective
Date"), between Genetronics, Inc. ("Genetronics"), a California corporation
located at 11199 Sorrento Valley Road, San Diego, CA 92129 and Gunter A.
Hofmann, Ph.D., having an address at 3750 Riviera Drive, #6, San Diego,
California 92109 ("Consultant").

                                  I. BACKGROUND

1.1 Genetronics desires that Consultant provide consulting services to
Genetronics for the purpose of advising Genetronics management and scientific
staff on matters concerning the business of Genetronics, including but not
limited to research, development, and intellectual property matters ("Field").

1.2 Consultant has agreed to provide services in the Field, pursuant to the
terms and conditions that follow.

                             II. CONSULTING SERVICES

2.1 Consultant agrees to perform consulting services, as set forth in this
Section II, beginning as of the Effective Date and terminating upon the later of
(i) January 6, 2001, (ii) the date of expiration or termination of the stock
option agreement entered into by Genetronics and Consultant as of November 12,
1999 ("New Options"), or (iii) the date of expiration or termination of the last
stock option agreement between Genetronics and Consultant in effect as of the
Effective Date of this Consulting Services Agreement ("Existing Options") (the
"Term"). The parties acknowledge that the New Options will naturally expire on
November 11, 2004, and the latest natural expiration date of the Existing
Options is October 19, 2003. For the sake of

                                       1
<PAGE>   2

clarity, the parties acknowledge that the New Options agreement and each
Existing Options agreement shall be terminated on the date all options granted
pursuant to such agreement have been exercised.

2.2 Consultant agrees to advise Genetronics management, scientists and/or other
Genetronics consultants in the Field as requested by Genetronics ("Services").
Services shall include, but not be limited to, telephone time; on-site advising
at Genetronics, or elsewhere; review of written documents; and/or preparation of
written documents.

2.3 Services shall be provided on an as needed basis, as requested by
Genetronics and pursuant to availability of Consultant. Consultant agrees to
make reasonable accommodations in his schedule if necessary to provide requested
Services.

2.4 Consultant shall report to James Lierman, Chief Operating Officer of
Genetronics, or his delegate, when performing Services pursuant to this
Agreement.

                                III. COMPENSATION

3.1 In consideration of Services, Genetronics shall compensate Consultant
directly as follows during the terms of this Agreement:

        a. Genetronics shall pay Consultant One Thousand Dollars ($1,000) per
full day of Services provided pursuant to Genetronics request ("Rate"), which
Rate shall be prorated in the event less than a full day of Services is
provided.

        b. Payment shall be made upon receipt of an invoice for Services
rendered. Consultant agrees to submit an invoice no more frequently than one
time per month.

3.2 The compensation set forth in Section 3.1 does not include expenses incurred
pursuant to

                                       2
<PAGE>   3

rendering Services. Genetronics shall reimburse Consultant for all reasonable
living and transportation expenses incurred by Consultant pursuant to rendering
requested Services or Excess Services, provided such expenses are approved in
writing by Genetronics prior to being incurred. Reimbursement shall be made
directly to Consultant upon submission to Genetronics of an invoice that
includes original receipts.

3.3 Consultant shall maintain true and correct records for time spent fulfilling
obligations under this Agreement and all transactions related thereto, for at
least twenty-four (24) months after termination of this Agreement.

                                       3
<PAGE>   4

                 IV. NO CONFLICT OF INTEREST AND NO COMPETITION

4.1 Consultant acknowledges that no prior or existing relationships exist which
would prevent Consultant from entering into and fulfilling all obligations under
this Agreement.

4.2 Consultant shall not disclose to Genetronics any information, suggestion,
product, product development, or process with respect to which Consultant is
under any actual or implied duty to any third party to keep secret or to advise,
suggest, or develop such information, and nothing in this Agreement shall impose
an obligation on Consultant to act contrary to any such actual or implied duty
to others. Genetronics shall be free to use all information that is disclosed by
Consultant to Genetronics without any further obligation to Consultant.

4.3 Genetronics wishes to avoid any possibility of conflict arising in the
future. Therefore, if any specific issue or project brought to the attention of
Consultant by Genetronics poses a potential conflict of interest, Consultant
will immediately advise Genetronics and Genetronics shall not request Services
on that specific issue or project.

4.4 No Competition

        a. Consultant acknowledges that development of, and maintaining
proprietary rights in, instruments, hardware, applicators and other equipment
related to electroporation-mediated delivery of compositions, such as drugs and
genes ("Genetronics Equipment") is a primary focus of Genetronics' current
business and future goals. Consultant also acknowledges that research and
development of electrically-assisted delivery of compositions to experimental
animals and human subjects, for a variety of biological and pathological fields
("Genetronics Research"), is another current and future objective of
Genetronics.

        b. It would be detrimental to Genetronics' business if Consultant were
to assist Genetronics' competitors in the areas of Genetronics Research or with
instrumentation competitive with Genetronics Equipment.

                                       4
<PAGE>   5

        c. Consultant shall not use, promote, develop, or assist in the
development of, instrumentation that is competitive with Genetronics Equipment.
Further, Consultant shall not contract or collaborate, or otherwise assist, a
third party in the area of Genetronics Research. Consultant acknowledges and
agrees with these restrictions.

4.5 Consultant warrants and represents that he is not aware that any
relationship presently exists which is in conflict with the provisions of this
Section IV, and that he has disclosed to Genetronics any other consulting or
business relationships that may possibly be related to this Agreement.

                           V. CONFIDENTIAL INFORMATION

5.1 Genetronics shall disclose confidential information to Consultant directly
or indirectly, with or without notice of its confidential nature. Accordingly,
Consultant agrees to hold all information disclosed to Consultant by Genetronics
in confidence and neither disclose the same to others nor use the same for any
purpose other than as provided herein without the written permission of
Genetronics. Upon request, Consultant will return to Genetronics all written
information supplied to Consultant by Genetronics, or generated by Consultant on
behalf of Genetronics, including all copies thereof..

5.2 Consultant agrees that all technical information, including any reports,
relating to Genetronics developed by Consultant in connection with Services
under this Agreement, shall be the property of Genetronics and subject to the
confidentiality and nonuse provisions set forth herein.

5.3 The duty of confidentiality and nonuse shall not apply to any information
disclosed to Consultant by Genetronics which, through no act or failure to act
on the part of Consultant:

                                       5
<PAGE>   6

        a. is or becomes public information,

        b. Consultant has in his possession at the time of disclosure by
Genetronics, other than by previous disclosure by Genetronics or through his
previous employment relationship with Genetronics,

        c. is furnished to Consultant by a third party without restriction on
disclosure, provided the third party is not related to this Agreement or to
Services rendered,

        d. is developed by or for Consultant outside the scope of this
Agreement, or

        e. Consultant has an obligation to disclose under law, including but not
limited to those promulgated by the FDA, SEC and/or USPTO, provided Genetronics
is given a reasonable opportunity to review the planned disclosure and discuss
the need for such.

                                 VI. INVENTIONS

6.1 Any inventions, discoveries and improvements, patentable or unpatentable,
that arise out of Services provided by Consultant under this Agreement and for
which Consultant is an inventor or coinventor, as determined under U.S. patent
law, ("Inventions") shall belong to Genetronics.

6.2 Consultant shall promptly and fully disclose all Inventions that arise out
of Services provided by Consultant under this Agreement to Genetronics and
cooperate with Genetronics or with its attorneys as may be reasonably required
in order to obtain patent and copyright protection therefor, including the
signing of any proper assignments, affidavits, applications and the like.
Furthermore, Consultant agrees to assign or otherwise transfer any and all
property rights, including all patent rights and all copyrights in materials
related to Services, domestic and foreign, resulting therefrom to Genetronics.

                                       6
<PAGE>   7

6.3 Consultant represents and warrants that he has the right to agree to the
terms of Sections 6.1 and 6.2 and is not bound by an obligation of assignment to
a third party with respect to Inventions, as defined herein.

                              VII. OTHER PROVISIONS

7.1 In performing Services for Genetronics pursuant to this Agreement,
Consultant shall be acting in the capacity of an independent contractor to
Genetronics and not as an employee of Genetronics or any of its subsidiaries or
affiliated companies. Accordingly, although Genetronics shall specify the
general nature of the work to be performed and the goals to be met, the details
of performing such work and meeting such goals shall be determined by
Consultant. Pursuant to this Agreement, Consultant shall not be entitled to any
benefits Genetronics offers its employees.

7.2 Consultant is not an agent of Genetronics pursuant to this Agreement and is
not authorized to make any representation, contract or commitment on behalf of
Genetronics as a Consultant.

7.3 Consultant will be solely responsible for all tax returns and payments
required to be filed with or made to any federal, state or local tax authority
with respect to Consultant's performance of Services and receipt of fees under
this Agreement. Consultant will regularly report amounts paid to Consultant by
filing form 1099-MISC with the Internal Revenue Service as required by law.
Because Consultant is an independent contractor, Genetronics will not withhold
or make any payments for social security, unemployment insurance or disability
insurance contributions, or obtain Workers' Compensation Insurance on
Consultant's behalf. Consultant agrees to accept exclusive liability for
complying with all applicable state and federal laws governing self-employed
individuals, including obligations such as payment of taxes, social security,
disability and other contributions based on fees paid to Consultant under this
Agreement. Consultant hereby agrees to indemnify and defend Genetronics against
any and all such taxes or

                                       7
<PAGE>   8

contributions, including penalties and interest.

7.4 This Agreement may be terminated earlier than the Term set forth in Section
2.1 , only upon mutual agreement of the parties. Provisions of compensation,
confidentiality, nonuse, and invention shall survive termination or expiration
of this Agreement by any mechanism.

7.5 This Agreement cannot be assigned by Consultant.

7.6 Any amendment or modification to this Agreement shall be valid only if in
writing and signed by both parties.

7.7 This Agreement will be governed by the laws of the State of California and,
to the extent applicable, the laws of the United States of America, without
regard to the place this Agreement is to be performed or where this Agreement
was made. Any dispute arising under this Agreement that the parties cannot
resolve by good faith negotiation and discussion shall be decided by binding
arbitration, conducted according to rules and guidelines to which the parties
shall jointly agree after good faith negotiation. In the event the parties
cannot agree on such rules and guidelines within 30 days of beginning such
negotiation, the parties hereby agree that the rules and guidelines of the
American Arbitration Association shall apply to resolve the dispute.

                                       8
<PAGE>   9

        Agreement to the foregoing is indicated by the signatures below:

GENETRONICS, INC.                             GUNTER A. HOFMANN, PH.D.

By:  /s/ Martin Nash                          By:   /s/  Gunter A. Hofmann
    -------------------------------------         ------------------------------
    Martin Nash                                   Gunter A. Hofmann, Ph.D.
    President and Chief Executive Officer

Date:  12/06/99                               Date:      12/06/99
      -----------------------------------           ----------------------------

                                       9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]